Suri Anish
Known title: PRESIDENT AND CSOCIK: 0001739130
Suri Anish's purchase track record
Suri Anish has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/25/2023 | CUE | $11K | -12.5% | -28.0% | +15.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| CUE | ▲ Buy | Open Market | 4,000 | $11K | 8/25/2023 | View on chart |
| CUE | ▲ Buy | Option Exercise | 16,668 | — | 3/31/2022 | View on chart |
| CUE | ▼ Sell | Tax Withholding | 7,068 | $34K | 3/31/2022 | View on chart |
| CUE | ▲ Buy | Option Exercise | 8,000 | $66K | 11/15/2021 | View on chart |
| CUE | ▼ Sell | Open Market | 8,000 | $144K | 11/15/2021 | View on chart |
| CUE | ▲ Buy | Option Exercise | 20,000 | $128K | 11/11/2021 | View on chart |
| CUE | ▼ Sell | Open Market | 20,000 | $301K | 11/11/2021 | View on chart |
| CUE | ▼ Sell | Tax Withholding | 14,134 | $183K | 10/6/2021 | View on chart |
| CUE | ▲ Buy | Option Exercise | 33,334 | — | 10/3/2021 | View on chart |
| CUE | ▲ Buy | Option Exercise | 20,000 | $128K | 9/23/2021 | View on chart |
| CUE | ▼ Sell | Open Market | 20,000 | $305K | 9/23/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
Cue Biopharma CUE-221 Meets Phase II Goals for Hives
Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.
Cue Biopharma CUE-221 Meets Phase II Goals for Hives. Cue Biopharma reported that its drug CUE-221 met Phase II goals in chronic spontaneous urticaria, showing durable responses. The news highlights potential for longer-lasting relief compared to current treatments. Despite positive results, the stock has experienced an unwarranted slide, though it remains well below the average analyst target.